Ratos (RATO) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
21 Oct, 2025Executive summary
Earnings and profitability increased despite subdued and uncertain market conditions, driven by efficiency initiatives and cost control, with early signs of improvement emerging.
Net sales for Q3 2025 were SEK 4,165m, down 9% year-over-year, while adjusted EBITA rose 31% to SEK 373m.
Profit for the period reached SEK 444m, compared to a loss of SEK 219m in Q3 2024.
Positive non-recurring items, notably a SEK 300m arbitration award related to Diab, boosted results.
Product solutions segment delivered strong performance and organic growth, while industrial services and construction/services faced challenges.
Financial highlights
Adjusted EBITA rose to SEK 373m from SEK 286m, a 31% increase, with margin improving to 9.0% from 6.2%.
Sales declined 9% year-over-year, mainly due to structural changes and negative organic growth.
Adjusted EPS increased to 0.43 from 0.05 year-over-year.
Cash flow from operations improved to SEK 868m from SEK 277m, more than tripling year-over-year.
Operating profit was SEK 606m, up from a loss of SEK 25m in Q3 2024.
Outlook and guidance
No formal forecast provided; management notes no deterioration in underlying market sentiment for infrastructure, with early signs of recovery and continued focus on operational improvements.
Consumer confidence is showing signs of improvement, and defense sector demand remains strong.
Automotive consultancy demand remains weak, but stabilization is expected early next year.
Market uncertainty and subdued demand are expected to persist, but ongoing efficiency measures are anticipated to support profitability.
Latest events from Ratos
- Adjusted EBITA rose 17% to SEK 1,931m, with improved leverage and major restructuring.RATO
Q4 20254 Mar 2026 - Earnings and margins improved despite 9% lower sales, with strong order intake and cash flow.RATO
Q2 20243 Feb 2026 - Strong cash flow and stable earnings offset sales decline amid major restructuring.RATO
Q3 202419 Jan 2026 - Adjusted EBITA rose, but non-recurring items from Plantasjen led to lower reported profit.RATO
Q4 202423 Dec 2025 - Adjusted EBITA up 32% with strong order intake and Plantasjen turnaround.RATO
Q1 202528 Nov 2025 - Margin expansion and major capital gains achieved amid challenging market conditions.RATO
Q2 202516 Nov 2025